Gene of the Month – May: CPS1
CPS1 encodes an enzyme that is located in the mitochondrial matrix of liver cells and epithelial cells in the intestinal mucosa and controls the conversion of ammonia into carbamoyl phosphate. Deficiency of carbamoyl phosphate synthetase I (CPS1) leads to toxic accumulation of ammonia in blood, which can cause severe brain damage or even death.
For their gene therapeutic approach, the researchers used the so called base editing technique. This is a modified form of the CRISPR/Cas system allowing to precisely rewrite a single DNA base at a specific site in the genome, without cutting the DNA double strand. The base editing complex to rewrite one of the two disease-causing compound heterozygous variants (p.Q335X) was administered intravenously and transported to the liver using lipid nanoparticles. Unlike viral vectors, they can be given more than once. After two administrations, early clinical results showed that the boy can now tolerate more protein in his diet and his ammonia-lowering medication has been reduced. However, a liver biopsy has not yet been performed to confirm the results directly in the tissue.
Musunuru K, Grandinette SA, Wang X, … Ahrens-Nicklas RC. Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med. 2025 May 15. doi: 10.1056/NEJMoa2504747. Epub ahead of print.